TOBI: reducing the impact of pseudomonal infection.
Pseudomonas aeruginosa infection is associated with impaired lung function and reduced life expectancy in cystic fibrosis patients. Tobramycin nebulizer solution (TOBI, Chiron Corporation Ltd, Hounslow) has been specifically formulated for use against P. aeruginosa infection in the lung.
Govan
John
J
Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh EH8 9AG.
D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology / Q000503:physiopathology; D004351:Drug Resistance; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D009330:Nebulizers and Vaporizers; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000503:physiopathology; D011550:Pseudomonas aeruginosa; D014031:Tobramycin / Q000008:administration & dosage*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D014031:Tobramycin